Nature Search

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

In this study, the authors report that post-vaccination neutralizing and binding antibody levels in the ENSEMBLE trial associate with Ad26.COV2.S vaccine efficacy (VE) against severe-critical COVID-19, with substantial VE even at unquantifiable neutralizing antibody titer.

Lindsay N. Carpp
Ollivier Hyrien
Griet A. Van Roey
ResearchOpen Access12 Nov 2024
Nature Communications

Volume: 15, P: 1-18
Post-exposure vaccine protection of CTH522/CAF^®01 against reinfection with Chlamydia trachomatis requires Th1/Th17 but not Th2-immunity

Nina Dieu Nhien Tran Nguyen
Sharmila Subratheepam
Jes Dietrich
ResearchOpen Access02 Apr 2025
npj Vaccines

Volume: 10, P: 1-11
MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

There is a requirement for improved adjuvants to improve responses to vaccines, including adjuvants that induce Th17 cells. Here, the authors use a MINCLE and TLR9 agonist-based vaccine adjuvant and show induction of Th17 and mucosal immune responses to vaccine recall antigens in mice and non-human primate models of vaccination.

Joshua S. Woodworth
Vanessa Contreras
Rasmus Mortensen
ResearchOpen Access17 Oct 2024
Nature Communications

Volume: 15, P: 1-16
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Gold-standard evidence for correlates of protection is provided by analysis of a randomized phase 3 trial of Ad26.COV2.S for protection against moderate to severe-critical COVID-19 disease.

Youyi Fong
Adrian B. McDermott
Ruben O. Donis
Research10 Nov 2022
Nature Microbiology

Volume: 7, P: 1996-2010
Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice

Authors present a comparative immunological characterisation of Chlamydia vaccine, CTH522/CAF®01, in mice and humans. Findings suggest the mouse to be a good predictor of human immunity to the Chlamydia vaccine CTH522/CAF®01, and long-lasting protection in the mouse further supports the development of this promising vaccine candidate.

Anja W. Olsen
Ida Rosenkrands
Frank Follmann
ResearchOpen Access23 Feb 2024
Nature Communications

Volume: 15, P: 1-18
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

Niels Peter H. Knudsen
Anja Olsen
Else Marie Agger
ResearchOpen Access21 Jan 2016
Scientific Reports

Volume: 6, P: 1-13
Publisher Correction: A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

Anja Weinreich Olsen
Ida Rosenkrands
Frank Follmann
Amendments and CorrectionsOpen Access30 Aug 2022
npj Vaccines

Volume: 7, P: 1
A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

Anja Weinreich Olsen
Ida Rosenkrands
Frank Follmann
ResearchOpen Access19 Apr 2021
npj Vaccines

Volume: 6, P: 1-11
Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge

Nina Dieu Nhien Tran Nguyen
Anja W. Olsen
Jes Dietrich
ResearchOpen Access23 Jan 2020
npj Vaccines

Volume: 5, P: 1-12

Search

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Post-exposure vaccine protection of CTH522/CAF^®01 against reinfection with Chlamydia trachomatis requires Th1/Th17 but not Th2-immunity

MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice

Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens

Publisher Correction: A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

A Chlamydia trachomatis VD1-MOMP vaccine elicits cross-neutralizing and protective antibodies against C/C-related complex serovars

Parenteral vaccination protects against transcervical infection with Chlamydia trachomatis and generate tissue-resident T cells post-challenge

Search

Quick links

Search

Filter By:

Search

Quick links